Neurogenerative Diseases - 14

Several proteins involved in normal mitochondrial
or lysosomal functioning such as Parkin, LIMP2, and
PINK115 are found to be mutated in PD. As a result,
affected cells are subjected to increased oxidative
stress and eventually cell death. Additionally,
mutations in proteins such as RME-8 (required for
receptor-mediated endocytosis) and optineurin
(important for the maintenance of the Golgi
complex and membrane trafficking) have also been
identified as contributing to PD pathology.16,17 In
Figure 3, we showcase representative validation
data for antibodies against several of these targets
that can be used across applications, including
immunofluorescence and western blotting. Table
2 provides a list of antibodies against a variety of
important PD targets.
Target protein

Protein function

Cat. No.

Ataxin3

Protein clearance

711823

DENND5A

Vesicle-mediated transport and
RAB-activating guanine nucle- 702789
otide exchange factor (GEF)

DJ-1 (PARK7)

Molecular chaperone

PA5-13404

DNAJC13 (RME8)

Membrane trafficking

702773

DNML1

Clathrin-mediated endocytosis 702782

LIMP2

Lysosomal membrane protein

conditions, tau is soluble and unfolded; however,
under pathological conditions in Parkinson's
or Alzheimer's disease, misfolding of tau leads
to insoluble neurofibrillary tangles (NFTs)-a
pathological effect called a tauopathy.4-6,21 In such
pathology, hyperphosphorylation of tau causes
protein aggregation and accumulation, which in turn
damages neurons and disrupts axonal transport.17,18,21
Although alpha-synuclein dysregulation is a possible
cause of Parkinson's disease, it has recently been
reported that both alpha-synuclein and tau are
present in the same Lewy body aggregate in many
postmortem brains with Parkinson's disease and
dementia.4-6 Consequently, clinicians and researchers
alike are focusing on the link between tau and alphasynuclein in Parkinson's disease at the molecular
level.4-6,10 Invitrogen primary antibodies against total
tau as well as several important phosphorylated
forms have been published and highly cited
in publications. Figure 4 shows representative
validation data for some of these antibodies, and
Table 3 provides a list of antibodies against these
important Parkinson's disease targets.

702770

Mitofusin-2 (MFN2) Mitochondrial maintenance

711803

Optineurin

Membrane trafficking

711879

alpha-Synuclein

Regulation of
neurotransmitter release

PA5-17239

TMEM230

Synaptic vesicle recycling

702792

VAMP1

Vesicular transport

702787

Table 2. Suggested Antibodies for Parkinson's Research

Target protein

Cat. No.

Tau (clone HT7)

MN1000, MN1000B
(biotin conjugate)

Tau (clone TAU-5)

AHB0042, MA5-12808,
MA5-12805 (biotin conjugate)

Tau (clone T46)

13-6400

Phospho-Tau (Ser202, Thr205)
(clone AT8)

MN1020, MN1020B
(biotin conjugate)

Phospho-Tau (Thr231) (clone AT180) MN1040

The link between alpha-synuclein
and tau in Parkinson's disease
Tau, a member of the microtubule-associated
protein family (MAPT), is associated with
microtubule stabilization, membrane binding, and
axonal transport.17-20 Under normal physiological

Phospho-Tau (Thr212, Ser214)
(clone AT100)

MN1060

HSP90 beta (clone H9010)

37-9400

Phospho-HSP27 (Ser15)

PA1-018

Phospho-HSP27 (Ser85)

PA1-005

Table 3. Suggested Antibodies Against Tau

14
Neurogenerative Diseases

Table of Contents for the Digital Edition of Neurogenerative Diseases
